Department of Medicine, Endocrinology, Metabolism and Geriatrics, University of Modena and Reggio Emilia, NOSE U.O. Medicina ad indirizzo metabolico-nutrizionistico, Via Giardini 1355, 41126, Modena, MO, Italy.
Intern Emerg Med. 2012 Oct;7 Suppl 3:S227-31. doi: 10.1007/s11739-012-0821-x.
Fabry disease is an X-linked inherited lysosomal disorder due to dysfunctions of the lysosomal enzyme alpha-galactosidase A, causing insufficient breakdown of glycolipids, which are stored in the eyes, kidneys, autonomic nervous system, skin, vessels and cardiovascular system. Manifestations of Fabry disease include progressive renal and cardiac insufficiency, neuropathic pain, stroke and cerebral disease, skin and gastrointestinal symptoms. Clinical onset usually occurs in childhood, but many severe patients are diagnosed in adulthood. Females may be severely affected as males and both may die prematurely due to stroke, heart disease and renal failure. Enzyme replacement therapy can stabilize or reduce the progression of the disease. There is a need to improve the knowledge of Fabry disease, as an early therapy may prevent complications of the disease. This brief overview aims to raise awareness of the signs and symptoms of Fabry disease and to summarize the effects of treatments.
法布瑞氏病是一种 X 连锁遗传性溶酶体贮积病,由于溶酶体酶α-半乳糖苷酶 A 的功能障碍,导致糖脂分解不足,这些糖脂在眼睛、肾脏、自主神经系统、皮肤、血管和心血管系统中储存。法布瑞氏病的表现包括进行性肾功能和心功能不全、神经病理性疼痛、中风和脑部疾病、皮肤和胃肠道症状。临床发病通常发生在儿童期,但许多重症患者在成年期才被诊断出来。女性可能像男性一样受到严重影响,并且两者都可能因中风、心脏病和肾衰竭而过早死亡。酶替代疗法可以稳定或减缓疾病的进展。需要提高对法布瑞氏病的认识,因为早期治疗可能预防疾病的并发症。本简要综述旨在提高对法布瑞氏病的体征和症状的认识,并总结治疗效果。